{"schema_version":"secwatch.filing_event.v1","accession":"0001378325-26-000035","form_type":"8-K","ticker":"CV","cik":"0001378325","company_name":"CapsoVision, Inc","filed_at":"2026-08-13T20:07:15+00:00","discovered_at":"2026-08-13T20:10:02.663337+00:00","generated_at":"2026-08-13T20:10:56.853941+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CapsoVision Q2 revenue $3.6M (+10% YoY), gross margin 51%, ATM up to $100M","bullets":["Q2 revenue $3.6M, up 10% YoY; gross margin 51% vs 55% on pricing pressure and tariffs.","Operating expenses $9.5M, up $3.0M YoY; cash $9.1M at June 30, 2026.","Entered ATM equity offering up to $100M with Cantor Fitzgerald; 3% commission.","Launched AI Highlights™ internationally; FDA clearance expected by end of Q3 2026.","Appointed David S. Shields, M.D. to Board effective July 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001378325-26-000035","json":"https://secwatch.observer/filing/0001378325-26-000035.json","markdown":"https://secwatch.observer/filing/0001378325-26-000035.md","text":"https://secwatch.observer/filing/0001378325-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/0001378325-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/cv-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:10:56.853941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}